USPTO serial 79403077
KALDENN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 12, 2025
- Examiner
- OAKES, JEFFREY ALLEN
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with KALDENN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jeffrey H. Handelsman
Jeffrey H. Handelsman Greenblum & Bernstein, P.L.C.1950 Roland Clarke PlaceReston, VA 20191-1411United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical substances, chemical materials and chemical products for use in medicine production, namely, chemical additives and active chemical ingredients for use in the manufacture of radiopharmaceutical preparations and pharmaceuticals for detecting and treating coronary diseases and coronary artery diseases; chemical substances, chemical preparations and chemical products for use in radiopharmaceutical product manufacture, namely, chemical additives and active chemical ingredients for use in the manufacture of radiopharmaceutical preparations and pharmaceuticals for detecting and treating myocardial ischaemia; active chemical ingredients for use in manufacture of radiopharmaceutical preparations against cancer; diagnostic preparations for scientific use or for research; diagnostic reagents for scientific use or for research; radioactive preparations for laboratory use for scientific purposes; contrast agents for molecular imaging other than for medical use; rubidium; strontium | ACTIVE | — |
| 005 | Radiopharmaceutical products, namely, radioactive substances for use in nuclear medicine; radioactive products for medical use, namely, radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; radioactive substances for medical use; isotopes for medical use; radiopharmaceutical preparations for medical use made from radiopharmaceutical generators, namely, for the detection and treatment of cancers, coronary diseases, coronary artery diseases, heart diseases and myocardial ischaemia; diagnostic radiopharmaceutical preparations; reagents and substances for medical diagnostic purposes; diagnostic biomarking reagents for medical use; contrast products being media for use with medical imaging equipment; cardiovascular medicines used in myocardial infarction treatment; contrast agents being media for use with molecular imaging equipment for medical use | ACTIVE | — |
| 010 | Radiopharmaceutical generators for medical use being medical generators specially adapted for medical, diagnostic and therapeutic purposes, namely for use in the production and transportation of nuclear medicines, radioactive substances for medical purposes, radiopharmaceutical products and radiopharmaceutical medicines; radioactive and radiopharmaceutical product generators for medical use being medical generators specially adapted for medical nuclear medicine purposes, namely for use in the production and transportation of nuclear medicines, radioactive substances for medical purposes, radiopharmaceutical products and radiopharmaceutical medicines; rubidium-82 generators for medical use being medical generators specially adapted for medical, diagnostic and therapeutic purposes, namely for use in the production and transportation of nuclear medicines, radioactive substances for medical purposes, radiopharmaceutical products and radiopharmaceutical medicines; medication injectors for medical use, namely, medical fluid injectors and injection devices for pharmaceuticals and radiopharmaceutical products; radiopharmaceutical medicine injectors being injection devices; radioactive and radiopharmaceutical product injectors for medical use being injection devices for pharmaceuticals, radioactive products and radiopharmaceutical products; automatic injectors being injection devices for administering radiopharmaceutical products; injectors of rubidium-82 to patients for medical use, namely, medical fluid injectors and injection devices for pharmaceuticals, radioactive products and radiopharmaceutical products; magnetic resonance tomography apparatus, namely, magnetic resonance imaging apparatus for medical purposes; medical equipment, namely, computed tomography apparatus; tomographic scanners for nuclear medicine, namely, X-ray CT scanners; medical apparatus for diagnosing suspected heart attacks | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by NAOGEN PHARMA
- Other trademarks owned by NAOGEN PHARMA
- Other trademarks owned by NAOGEN PHARMA
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Similar marks named KALDENN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 9, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 26, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 19, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 21, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 21, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 12, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jan 27, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 27, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Nov 12, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 12, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 12, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 24, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 24, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 18, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 21, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 15, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 15, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 15, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 15, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 15, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| May 15, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 15, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 15, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 15, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 29, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 12, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 12, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 28, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 27, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 26, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 3, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 3, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 29, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |